Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion type Assertion NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_head.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion wasGeneratedBy ECO_0000203 NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion wasDerivedFrom befree-20150227 NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion SIO_000772 18048643 NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion evidence source_evidence_literature NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.
- NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219179.RAPHL4tA8ZQmL6DcFek7ztdwNbKrdUTXyQpiqG6eTMii4130_provenance.